Penumbra 2025-26: Thrombectomy 20-21%, GM 70%+ Target, Op Margin Inflection

FY25 revenue $1.40B (+17%); op income $189M (vs $9M FY24, +1939%); NI $178M (vs $14M FY24, +1168%); EPS $4.52 (vs $0.36, +1156%). FCF $175M (+19%). Q3 FY25 latest disclosed: revenue $354.7M (+17.8% reported / +16.9% CC); US revenue $275M (+21.5%); thrombectomy $192M (+18.5%); VTE franchise +34%; US embolization + access $83M (+29.2%); International $79.7M (+6.6% reported / +3% CC); gross margin 67.8% (+130bp YoY); operating income $48.8M (13.8% of revenue). Multi-year FY25 raised guidance: total revenue $1.375-$1.380B (13-15% YoY growth); reiterated US thrombectomy 20-21%; maintained gross + operating margin expansion. Gross margin on track to exceed 70% by 2026. FDA-cleared products in 2025: Lightning Bolt 16, Flash 3.0, Ruby XL. Thunderbolt FDA review ongoing. STORM-PE trial showed CAVT superiority vs anticoagulation alone in acute intermediate-high-risk PE. Built separate peripheral embolization sales force. China revenue $5M excluded from forecast. Total debt $220M (-2%); no dividend; no buyback FY25 (vs $100M FY24).

Key takeaways

• Op income +1939% to $189M; NI +1168% to $178M; EPS $4.52 (vs $0.36 FY24) — operating margin inflection. Penumbra's FY25 marked a structural inflection in profitability: operating income jumped from $9M (FY24) to $189M (FY25), with operating margin expanding from <1% to 13.5%. The inflection reflects (a) revenue scale to $1.40B, (b) gross margin expansion to 67.8%+ (130bp Q3 YoY), (c) operating leverage on scaled R&D + SG&A base, (d) China exit reducing low-margin drag. Multi-year operating margin trajectory toward peer medical device benchmarks (20-25%+) is now visible.

• Q3 US thrombectomy +18.5%; VTE franchise +34% — flagship platform compounding. US thrombectomy (Penumbra's flagship clot removal franchise for stroke + peripheral vascular events + venous thromboembolism) delivered +18.5% Q3 revenue growth to $192M. The VTE (Venous Thromboembolism) franchise within thrombectomy grew +34% in Q3. CAVT (Computer Assisted Vacuum Thrombectomy) technology enhancement is the cleanest growth driver — newer-generation Lightning Bolt 16, Flash 3.0 + Ruby XL extend the platform.

• STORM-PE trial: CAVT superiority vs anticoagulation alone in acute intermediate-high-risk PE — multi-year market expansion catalyst. Enrollment completed in STORM-PE trial; results showed CAVT (Computer Assisted Vacuum Thrombectomy) plus anticoagulation superior to anticoagulation alone for acute intermediate-high-risk pulmonary embolism. This is a meaningful multi-year market expansion catalyst — STORM-PE results support reimbursement + clinical adoption + guideline integration for CAVT in PE treatment, expanding the addressable population beyond current high-risk PE indications.

• Gross margin 67.8% Q3 (+130bp YoY); on track to exceed 70% by 2026 — multi-year margin expansion runway. Q3 gross margin expanded 130bp to 67.8%. Management explicitly guided gross margin to exceed 70% by 2026. The gross margin expansion is multi-year in nature: (a) higher-margin CAVT mix shift, (b) volume / scale efficiency, (c) China exit benefit, (d) production / yield improvements. 70%+ gross margin combined with leveraging R&D + SG&A creates further operating margin expansion runway into FY27-28.

• Strategic commercial expansion: separate peripheral embolization sales force + Lightning Bolt + Flash + Ruby + Thunderbolt pipeline. Penumbra is investing in commercial team expansion: built a separate peripheral embolization sales force in 2025 (different focus / call point than thrombectomy). Multi-product pipeline: Lightning Bolt 16, Flash 3.0, and Ruby XL all FDA cleared in 2025; Thunderbolt under FDA review. The product cadence + commercial expansion sets up multi-year growth + market share gains across thrombectomy + embolization + neurovascular.

Business

Penumbra, Inc. is a global medical device company focused on neurovascular + peripheral vascular intervention, with multi-segment portfolio:

• Thrombectomy (Global) (~65% of revenue): CAVT technology for clot removal across stroke (neurovascular), VTE (deep vein + pulmonary embolism), peripheral arterial. Q3 thrombectomy global $230M; US thrombectomy $192M (+18.5%). Lightning Bolt 16 + Flash 3.0 + Ruby XL platform.
• Embolization + Access (~30%): Embolization coils + microcatheters + access devices for peripheral vascular interventions. Q3 US embolization + access $83M (+29.2%).
• Neurovascular Specialty (~5%): Stroke aspiration + delivery catheters + adjunctive devices. RED 72 SILVER LABEL.
• International (~24% Q3): Multi-region + China divest.

Strategic moves FY25:

• Operating income inflection: $9M (FY24) → $189M (FY25)
• Q3 US thrombectomy +18.5%; VTE +34%; embolization + access +29.2%
• Gross margin 67.8% Q3 (+130bp YoY); 70%+ target by 2026
• FDA cleared Lightning Bolt 16, Flash 3.0, Ruby XL in 2025
• Thunderbolt FDA review ongoing
• STORM-PE trial enrollment complete; CAVT superiority demonstrated in acute intermediate-high-risk PE
• Built separate peripheral embolization sales force
• China revenue $5M excluded from forecast (macro environment)
• Multi-year guidance raised through year
• No buyback FY25 (vs $100M FY24)

FY25 financial performance

The earnings progression: revenue grew steadily $847M → $1.40B (+66% over 3 years). Operating margin trajectory volatile: FY22 0.7% → FY23 6.9% → FY24 0.8% (commercial / inventory dynamics) → FY25 13.5% (operating leverage at scale). EPS jumped to $4.52 reflecting operating income inflection.

FCF $175M (+19%); capex stepped up to $64M (+201% YoY) reflecting capacity + R&D investment. Total debt minimal at $220M.

Capital allocation

• Capex: $-64M FY25 (+201% YoY) — capacity + R&D + commercial infrastructure investment.
• Dividends: $0 (no dividend; growth phase).
• Buybacks: $0 FY25 (vs $100M FY24); capital deployed to growth investment.
• Total debt: $220M (-2% YoY); minimal leverage.
• FCF: $175M FY25 (+19% YoY).
• Multi-year priority: R&D + commercial expansion + capacity build.

FY26 outlook (per Q3 FY25 raised guidance + general framework)

Note: Q4 FY25 specific call + FY26 guide pending. Multi-year framework: continued thrombectomy growth + embolization/access expansion + gross margin expansion + product pipeline + STORM-PE multi-year market expansion.

Key risks

Thrombectomy competitive landscape. Stryker (Trevo + Embolus), Medtronic (Solitaire), Johnson & Johnson Cerenovus (EmboTrap), Imperative Care, others compete in subsets. Multi-year competitive intensity.

Embolization + access competitive landscape. Boston Scientific, Terumo, Medtronic, Cook Medical compete. Multi-year competitive dynamics.

FDA regulatory + clinical trial. Multi-year FDA approval + clinical trial timing matter (Thunderbolt under review).

Reimbursement + coverage. Procedure reimbursement (CMS, commercial insurers, Medicare Advantage) affects adoption pace.

Hospital procedural volumes. Multi-year procedural recovery + capacity dynamics + staffing affect device demand.

International / FX. ~24% international revenue exposes Penumbra to FX volatility. China exit creates revenue / margin dynamics.

STORM-PE trial outcomes. Continued clinical evidence build-out; further trials needed for guidelines + reimbursement.

Manufacturing + supply chain. Multi-region manufacturing + specialty components.

Commercial team execution. Separate peripheral embolization sales force require multi-year scaling.

Inventory dynamics. Multi-year inventory + customer ordering pattern dynamics.

Margin trajectory execution. 70%+ gross margin target requires execution on mix + scale.

Litigation + product liability. Implanted / interventional devices carry multi-year liability exposure.

Customer concentration in key hospital systems. Multi-region hospital system relationships.

Clinical adoption pace. New CAVT indications + clinical adoption multi-year ramp.

M&A integration. Future M&A pipeline carries integration risk.

Bottom line

Penumbra FY25 is the operating margin inflection + multi-product pipeline year: revenue $1.40B (+17%); op income $189M (vs $9M FY24, +1939%); NI $178M (+1168%); EPS $4.52 (vs $0.36, +1156%). FCF $175M (+19%). Q3 latest disclosed: revenue $354.7M (+17.8% reported / +16.9% CC); US revenue $275M (+21.5%); thrombectomy $192M (+18.5%); VTE franchise +34%; US embolization + access $83M (+29.2%); International +6.6% / +3% CC; gross margin 67.8% (+130bp YoY); op income $48.8M (13.8% of revenue). FDA cleared Lightning Bolt 16 + Flash 3.0 + Ruby XL. Thunderbolt FDA review ongoing. STORM-PE trial demonstrated CAVT superiority in acute intermediate-high-risk PE. Built separate peripheral embolization sales force. FY25 raised guide $1.375-$1.380B; US thrombectomy 20-21%; gross margin 70%+ target by 2026. Capex $64M (+201%) — capacity + R&D investment.

FY26 framework: continued multi-segment compounding + gross margin expansion to 70%+ + operating margin further expansion + product pipeline (Thunderbolt + others) + commercial expansion + STORM-PE multi-year adoption + market expansion.

The risks are real — thrombectomy competitive landscape (Stryker, Medtronic, Johnson & Johnson Cerenovus, Imperative Care), embolization + access competitive landscape (Boston Scientific, Terumo, Medtronic, Cook Medical), FDA regulatory + clinical trial timing, reimbursement + coverage, hospital procedural volumes, international / FX, STORM-PE trial outcomes + further clinical evidence, manufacturing + supply chain, commercial team execution, inventory dynamics, margin trajectory execution, litigation + product liability, customer concentration, clinical adoption pace, M&A integration.

But the structural thesis (global medical device company + neurovascular + peripheral vascular intervention + thrombectomy CAVT technology platform + embolization + access + Lightning Bolt 16 + Flash 3.0 + Ruby XL all FDA cleared 2025 + Thunderbolt under FDA review + STORM-PE trial CAVT superiority demonstrated + gross margin 67.8% (+130bp) on track to >70% by 2026 + operating margin inflection from <1% to 13.5% + US thrombectomy +18.5% Q3 + VTE +34% + embolization +29.2% + multi-product pipeline + multi-region commercial expansion) is intact and FY25 confirms.

Quality medical device + neurovascular + peripheral vascular compounder mid-cycle, with multi-segment platform + CAVT technology leadership + STORM-PE clinical evidence + gross margin expansion + operating margin inflection + multi-product pipeline + commercial expansion + multi-year revenue compounding. The FY25 +17% revenue + operating margin 13.5% (from <1%) + NI +1168% + EPS $4.52 + Q3 thrombectomy +18.5% + VTE +34% + embolization +29.2% + GM 67.8% + STORM-PE results + Lightning Bolt 16 + Flash 3.0 + Ruby XL + Thunderbolt + 70%+ GM target by 2026 creates one of the cleaner medical device compounding setups for investors seeking exposure to thrombectomy + embolization + neurovascular + multi-year clinical evidence + margin expansion + commercial expansion. The conservative FY25-26 framework + clinical pipeline + STORM-PE multi-year adoption + commercial team scaling + 70%+ gross margin runway provides multiple paths to outperformance over a multi-year horizon. Competitive landscape + FDA regulatory + reimbursement + procedural volumes + clinical adoption pace remain ongoing risks, but the multi-segment diversification + CAVT moat + clinical evidence + commercial expansion + margin expansion runway support continued compounding through cycles.

Citations

• Penumbra, Inc. FY25 Form 10-K (filed February 2026, SEC EDGAR).
• PEN Q3 2025 earnings call, 2025-11-05 — Q3 revenue $354.7M (+17.8% reported / +16.9% CC); US revenue $275M (+21.5%); thrombectomy $192M (+18.5%); VTE franchise +34%; US embolization + access $83M (+29.2%); International $79.7M (+6.6% / +3% CC); gross margin 67.8% (+130bp YoY); operating income $48.8M (13.8% of revenue). Strong Q3 results, broad-based execution, enhanced competitive positioning. Gross margin on track to exceed 70% by 2026. FDA cleared Lightning Bolt 16 and Flash 3.0. Thunderbolt update with ongoing FDA review. STORM-PE trial showed CAVT superiority in PE treatment. Built separate peripheral embolization sales force. FY25 revenue guidance raised to $1.375-$1.380B. Reiterated 20-21% YoY US thrombectomy growth.
• PEN Q2 2025 / Q1 2025 earnings calls — supporting US thrombectomy + VTE + embolization + access + gross margin trajectory.
• Internal financial_statements view (consolidated annual + cash flow + capital structure).